University of Cologne | ClinicalTrials HQ

3 results · Page 1 of 1

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pivotal Study of N-acetyl-L-leucine for CACNA1A	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Dyskinesias, Neurologic Manifestations, Spinocerebellar Ataxias, Spinocerebellar Degenerations, atactic disorder, non-human animal, brain disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, episodic ataxia type 2, hereditary disease, inherited neurodegenerative disorder, nervous system disorder, neurodegenerative disease, spinal cord disorder, spinocerebellar ataxia type 6	Recruiting	Phase 3	2026-09-08		NCT07221292
Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse	Blood Protein Disorders, Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, cardiovascular disorder, hematologic disorder, hemorrhagic disease, immune system disorder, immunoproliferative disorder, lymphoproliferative syndrome, monoclonal gammopathy, neoplasm, plasma cell neoplasm, vascular disorder, vascular hemostatic disease	Active, not recruiting	Phase 2	2026-03-05		NCT04656951
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)	Congenital, Hereditary, and Neonatal Diseases and Abnormalities, DNA repair disease, Dyskinesias, Neurologic Manifestations, Nutritional and Metabolic Diseases, Primary Immunodeficiency Diseases, Spinocerebellar Ataxias, atactic disorder, non-human animal, ataxia telangiectasia, brain disorder, cardiovascular disorder, central nervous system disorder, cerebellar ataxia, cerebellar disorder, hereditary disease, immune system disorder, inborn error of immunity, metabolic disease, nervous system disorder, neurocutaneous syndrome, telangiectasis, vascular disorder	Active, not recruiting	Phase 3	2025-07-03		NCT06673056